Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in Geographic Atrophy (FILLY)
NCT02503332Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Sep 2015
- Primary completion
- Jul 2017
- Modality
- PEGylated Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, single-blind trial of pegcetacoplan in geographic atrophy (GA) (4 arms), sponsored by Apellis Pharmaceuticals. Primary endpoints: Least Square Mean Change From Baseline in Square Root GA Lesion Size at 12 months and Number of Subjects With Treatment Emergent Adverse Events at 12 months. Started Sep 2015; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02503332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503332.